(Reuters) - An updated experimental form of AbbVie Inc's (ABBV.N) Humira arthritis drug has clear advantages over the original that could help the company confront looming cheaper biosimilar forms of ...
AbbVie, already famous for its Humira strategy, forms another 'patent wall' around Imbruvica: report
AbbVie grew Humira into the world’s bestselling medicine in part through price hikes and an aggressive patenting strategy to defend against competition. The company is now deploying similar tactics to ...
March 5 (Reuters) - AbbVie Inc : * CEO says Pharmacyclics deal will boost earnings by more than 60 cents per share by 2019, ramp earnings thereafter * CEO says expects Pharmacyclics blood cancer drug ...
The U.S. Food and Drug Administration (FDA) approved Novartis' (NYSE:NVS) citrate-free high-concentration formulation (HCF) of Hyrimoz, a biosimilar to AbbVie's (NYSE:ABBV) blockbuster drug Humira.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback